New study aims to predict organ damage in cancer patients on immunotherapy

NCT ID NCT07131007

Recruiting now Knowledge-focused Sponsor: Hebei Medical University Fourth Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study enrolls 2000 cancer patients receiving immune checkpoint inhibitors. Researchers collect blood, urine, and stool samples before and after treatment to analyze genes, proteins, and other markers. The goal is to create a system that warns doctors early if a patient's organs are at risk of damage from immunotherapy. No new treatments are tested; this is purely observational.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a system that predicts organ damage early in cancer patients receiving immunotherapy, improving safety.
What could go wrong: This is an observational study, not a treatment trial. The system may not be accurate enough for real-world use, and results may take years to apply.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT NEOPLASM ORGAN DAMAGE

Contacts and locations

Locations

Fourth Hospital of Hebei Medical University
RECRUITING

Shijiazhuang, Hebei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.